Agios Pharmaceuticals (AGIO) Interest Expenses (2012 - 2026)

Agios Pharmaceuticals' Interest Expenses history runs 15 years deep, the most recent figure standing at $37.7 million for Q1 2026.

• Quarterly Interest Expenses rose 680.09% year-over-year to $37.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.7 million (up 99.76% YoY) and the FY2025 annual result came in at $365.6 million, up 32.67% from the prior year.
• Interest Expenses was $37.7 million for Q1 2026 at Agios Pharmaceuticals, up from $4.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $47.7 million in Q3 2025 and bottomed at $3.8 million in Q1 2022.
• A 5-year average of $9.1 million and a median of $4.7 million in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses rose 2.94% — and 2025, when it surged 917.59%.
• Agios Pharmaceuticals' Interest Expenses stood at $4.4 million in 2022, then increased by 2.96% to $4.6 million in 2023, then gained by 2.94% to $4.7 million in 2024, then advanced by 4.88% to $4.9 million in 2025, then soared by 667.09% to $37.7 million in 2026.
• Business Quant data shows AGIO's Interest Expenses at $37.7 million in Q1 2026, $4.9 million in Q4 2025, and $47.7 million in Q3 2025.